INKT
HEALTHCAREMiNK Therapeutics Inc
$11.21-0.33 (-2.86%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving INKT Today?
No stock-specific AI insight has been generated for INKT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.34$76.00
$11.21
Fundamentals
Market Cap$56M
P/E Ratio—
EPS$-2.93
Dividend Yield—
Dividend / Share—
ROE-12.4%
Profit Margin—
Debt / Equity—
Trading
Volume11K
Avg Volume (10D)—
Shares Outstanding5.0M
INKT News
20 articles- MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy ProgramsYahoo Finance·May 8, 2026
- Agenus to Provide First Quarter 2026 Financial Report and Corporate UpdateYahoo Finance·May 4, 2026
- MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal CancerGlobeNewswire Inc.·Apr 17, 2026
- MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026GlobeNewswire Inc.·Apr 3, 2026
- Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026Yahoo Finance·Apr 3, 2026
- MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell TherapyYahoo Finance·Apr 2, 2026
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International ConferenceYahoo Finance·Apr 1, 2026
- MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ...Yahoo Finance·Mar 31, 2026
- MiNK Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 31, 2026
- MiNK Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 31, 2026
- MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive MomentumYahoo Finance·Mar 31, 2026
- MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy ProgramsYahoo Finance·Mar 17, 2026
- Wall Street Stabilizes After Oil-Driven Volatility as US Equity Futures Waver Pre-BellYahoo Finance·Mar 10, 2026
- MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric CancersYahoo Finance·Mar 10, 2026
- C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric OncologyYahoo Finance·Mar 10, 2026
- Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate UpdateYahoo Finance·Mar 4, 2026
- MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone SymposiaYahoo Finance·Feb 4, 2026
- Agenus (AGEN) Q2 2025 Earnings Call TranscriptMotley Fool·Jan 27, 2026
- MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host DiseaseYahoo Finance·Jan 8, 2026
- MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid TumorsYahoo Finance·Nov 20, 2025
All 20 articles loaded
Price Data
Open$11.91
Previous Close$11.54
Day High$11.93
Day Low$11.50
52 Week High$76.00
52 Week Low$6.34
52-Week Range
$6.34$76.00
$11.21
Fundamentals
Market Cap$56M
P/E Ratio—
EPS$-2.93
Dividend Yield—
Dividend / Share—
ROE-12.4%
Profit Margin—
Debt / Equity—
Trading
Volume11K
Avg Volume (10D)—
Shares Outstanding5.0M
About MiNK Therapeutics Inc
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—